clinical trial · NCT04489771
A Study of Belzutifan (MK-6482) in Participants With Advanced Renal Cell Carcinoma (MK-6482-013)
Merck Sharp & Dohme LLC·phase2·completed·n = 154
Carcinoma, Renal CellBelzutifan
brief summary
This study will compare the efficacy and safety of two doses of belzutifan in participants with advanced renal cell carcinoma (RCC) with clear cell component after prior therapy. The primary hypothesis is that the higher dose of belzutifan is superior to the standard dose in terms of objective response rate (ORR).
started
Sep 13, 2020
primary completion
Feb 10, 2023
completion
Aug 25, 2026
last updated
Sep 24, 2026
official title
Phase 2 Study of MK-6482 in Participants With Advanced Renal Cell Carcinoma
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol